Promotes healthy cell immune function*
- Promotes antibody production
- Supports a healthy immune system
- Clinically studied and developed in Japan
$69.96 — or subscribe and save 20%
Out of stock
AOR’s AHCC® contains oligosaccharide extracted from mushrooms grown in rice bran. Since the late ’80s, when this method was developed in Japan, it has been used to help support immunity in an effective way. Oligosaccharide is a well-researched extract shown to be effective in highly vulnerable populations, making it a highly sought after immune-boosting supplement.
The human body is constantly exposed to bacteria and it depends on the immune system to help destroy harmful bacteria and stay healthy. In order to do that, the body needs to get the right nutrients on a consistent basis. Lack of consistency in maintaining a balanced diet, along with the demands of long hours of work, school, family commitments, and a lack of restful sleep can all diminish immunity.
A weakened immune system leaves the body susceptible to seasonal viruses and other ailments. Edible mushrooms are known for their nutritional properties. They contain different amounts of protein and fiber, along with vitamin B and selenium. Some mushrooms, such as shiitake mushrooms, have special properties that support the health of different systems in the human body.
AHCC® is a unique antioxidant and immune system modulator. AOR’s AHCC® contains one of the highest doses found on the market with the fewest additional ingredients. The active ingredients of AHCC® include acetylated alpha-glucan for optimal bioavailability.
AHCC® is an extracted compound derived from Shiitake mushroom. The active ingredients of AHCC® include alpha and beta glucans and polysaccharides of low molecular weight (5 kDaltons) for optimal bioavailability and immune support.*
AOR™ guarantees that all ingredients have been declared on the label. Made without wheat, gluten, nuts, peanuts, sesame seeds, sulfites, mustard, soy, dairy, eggs, fish, shellfish or any animal byproduct.
Take one capsule one to three times daily preferably without food, or as directed by a qualified health care practitioner.
Consult a health care practitioner before use if you are pregnant, lactating, have medical condition, or are taking any medication. Keep out of reach of children. Nausea and diarrhea have been known to occur, in which case, discontinue use.
- Immune system support
- Healthy inflammatory response
- Normal cell production and differentiation
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Mushroom mycelia extract of hybridized basidiomycetes (Lentinula edodes) mushrooms (with acetylated alpha-glucans), carnauba plant wax, dextrin (tapioca), cellulose (plant), alpha-cyclodextrin (vegetable)
Other ingredients: none. Capsule: hypromellose, purified water.
Ahn GH et al. The Clinical Effectiveness of AHCC Treatment in Cancer Patients with Progressive or Metastasized Cancers: An Observation of Immune Parameters. AHCC Research Association 8th Symposium, Sapporo, Japan, Aug. 2000
Cotran RS, Kumar V, Collins T. Robbins pathologic basis of disease. 6th ed. Toronto: W.B. Saunders Company. 1999.
Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004 Aug;21(2):137-48.
Hosokawa M. Combination of AHCC and Chemotherapy. Anti-Cancer Drugs, 9, 343-350, 1998
Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109
Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000 Nov 25;356(9244):1795-9.
Ishibashi H, et al. Prophylactic Efficacy of a Basidiomycetes Preparation AHCC against Lethal Opportunistic Infections in Mice. Yakugaku Zasshi, 120(8),715-719. 2000
Ishiguro A. Anti-Carcinogenic Activity of AHCC and PMP. The 2nd Annual Meeting of the Japanese Society for Alternative Medicine & Treatment. Oct. 1999.
Katsuaki Uno, Kenichi Kosuna, Bxiang Sun, Hajimi Fujii, Koji Wakame, Shizuko Chikumaru, George Hosokawa, Yuji Ueda. Active Hexose Correlated Compound (AHCC) Improves Immunological Parameters and Performance Status of Patients with Solid Tumors. Biotherapy 2000; 14(3):303-309
Matsui Y, Uhara J, Satoi S, Kaibori M, Yamada H, Kitade H, Imamura A, Takai S, Kawaguchi Y, Kwon A-H and Kamiyama Y. Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study. Journal of Hepatology 2002;37(1):78-86.
Matsushita K. et al., Combination therapy of active hexose correlated compound (AHCC) plus UFT significantly reduces the metastasis of rat mammary carcinoma, Anti-Cancer Drugs, 343-350, Sep 1998.
Prasad KN. Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their toxicity. Integr Cancer Ther. 2004 Dec;3(4):310-22.
Reuters. Report: More than half of U.S. cancer deaths could be prevented-Lifestyle changes would eliminate majority of cases. Washington. March 31, 2005
Rosenberg ES, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 407, 523 – 526 (28 September 2000)
Sun B, Wakame K, Mukoda T, Toyoshima A, Kanazawa and Kosuna K. Preventive Effect of AHCC on Carbon Tetrachloride Induced Liver Injury in Mice. Natural Medicine 51(4), 310-315. 1997
Uno K, Chikumaru S, Hosokawa T. Cancer immunotherapy by a phyto-polysaccharide (AHCC): its effects and strategy. AHCC Research Association 8th Symposium, Sapporo, Japan, Aug. 2000
Wakame K. Protective Effects of Active Hexose Correlated Compound (AHCC) on the Onset of Diabetes Induced by Streptozotocin in the Rat. Biomedical Research 20 (3) 145-152. 1999
Wang S et al. Preventive Effects of Active Hexose Correlated Compound (AHCC) on Oxidative Stress Induced by Ferric Nitrilotriacetate in the Rat. Dokkyo Journal of Medical Sciences 28(2-3). 745-752. 2001